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Introduction 
Canine sarcoptic mange caused by the burrowing epidermal mite, 
Sarcoptes scabiei var. canis, is highly contagious, intensely pruritic 
and one of  the most uncomfortable skin diseases that a dog can 
contract (Doering and Jensen, 1973). Mite infection occurs by di-
rect contact with an infested dog (or fox) or by contact with an in-
fected dog’s bedding (Curtis, 2004). And Sarcoptes scabiei is parasite 
of  considerable importance in canine veterinary practice. In many 
animal species, the prevalence of  scabies is very high and often 
confers the death of  the untreated animals (Kemp et al., 2004). 
The mite is also transmissible to humans. 
Canine scabies is often a progressive disease that is refractory to 
most symptomatic therapies (Bond, 1998). Of  the options avail-
able for treating S. scabiei infestation in dogs, many involve treating 
the entire body surface with an acaricidal dip or wash (Sosna and 
Medleau, 1992). Several treatments are usually recommended for 
complete control of  the infestation (Sosna and Medleau, 1992). 
Lime-sulfur or amitraz dips are usually effective and topical treat-
ment with fipronil was also reported to be useful (Curtis, 2004). 
Metaflumizone plus amitraz showed cure rates of  75% and 83% 
for the monthly and two-weekly regimens based on zero mite 
counts and/or resolution of  clinical signs (Fourie et al, 2007). Sys-
temic treatment is based on the macrocyclic lactones. Selamectin 
(Shanks et al., 2000; Six et al, 2000) and moxidection in combina-
tion with imidacloprid (Krieger et al., 2005) have been used as 
effective topical treatments. Off-label use of  macrocyclic lactones 
such as ivermectin and moxidectin at doses of  0.2–0.5 mg/kg 
given orally or by injection at treatment intervals of  1 or 2 weeks 
have been reported to be effective (Paradis, 1998; Wagner and 
Wendleberger, 2000; Fthenakis et al, 2000 Curtis, 2004). Other-
wise, some herbal products also showed active effects (Das, 1996; 
Tabassam et al, 2008).
Milbemycin oxime (MBO), 5-hudroxyimino derivatives of  milbe-
mycin A4 and A3 (A4:A3≥80:20) (Tsukamoto et al, 1991), is effec-
tive against endo- and ectoparasites (Bergvall, 1998; Holm, 2003; 
Bredal, 1998; White et al, 2001), and belongs to semisynthesis 
macrocylic lactone anthelminthics, was launched as a parasiticide 
for dogs. MBO is a parasite control drug effective in controlling 
or preventing several of  the most common parasitic diseases of  
dogs and cats. It is usually used to prevent heartworms (Stewart et 
al, 1992; Tagawa et al, 1993; Stewart et al, 1992; Snyder and Wise-
man, 2012; Snyder et al, 2011a; Snyder et al, 2011b; Blagburn et 
al, 2011) and control disease caused by hookworms (Blagburn et 
Abstract
Milbemycin oxime tablets were evaluated for efficacy against sarcoptic mange mites in naturally infested dogs. Sixty-five dogs were allocated 
to two groups and were housed individually. Fifty of  the dogs were treated orally with milbemycin oxime at the proposed dose. The other 
fifteen were treated orally with vehicle. Study day 0 was defined as the first day of  treatment administration. Dogs were treated on days 0, 7 
and 14, and efficacy was assessed by counting viable mites recovered from skin scrapings. To enumerate Sarcoptes scabiei mites, skin scrapings 
were taken on each of  Days-1, 14, 28, 42 and 56. Clinical signs of  mange and the extent of  sarcoptic lesions were evaluated on each dog when 
scrapings were made. Evaluation of  the efficacy of  the treatment was based on the absence of  mites supported by the absence of  clinical 
signs associated with canine sarcoptic mange. Treatment with milbemycin oxime at weekly intervals resulted in a rapid reduction of  mites and 
improved clinical signs. Percentage reductions in geometric mean mite counts for milbemycin oxime, compared with vehicle, on days 14, 28, 
42, and 56 were 90, 96, 100, and 100%, respectively. The overall cure rates at Day 56, based on zero mite counts and resolution of  clinical 
signs were 100% of  dogs. Weekly treatment with maximum dose (2.0g/kg) rate of  milbemycin oxime for continually three weeks, was effective 
against naturally acquired infestations of  sarcoptes scabiei in dogs, reducing mites counts by 100%.
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al, 1992; Humbert-Droz  et al, 2004; Niamatali et al, 1992; Bow-
man et al, 1990; Wade et al, 1991) in dogs and cats and certain 
whipworms in dogs (Blagburn et al, 1992; Reichard et al, 2007).
The objective of  the studies reported here was to evaluate the 
efficacy and safety of  milbemycin oxime, applied weekly for treat-
ment of  naturally occurring infestations of  S. scabiei on dogs. 
Materials and Methods
Test materials
The commercial formulation for dogs, containing 2mg milbemy-
cin oxime per pellet. The dosages of  milbemycin oxime was ad-
ministered ranged from 2.4 to 1.8 mg/kg of  bodyweight. 
Animals
Sixty-five dogs (27males, 28 females; age range: 6months to 6 
years; weight range: 8.3 to 11.2kg) with naturally acquired infes-
tations of  S. scabiei were used in these studies. The animals pre-
sented clinical signs of  sarcoptic mange including, erythematous 
lesions, crusts, alopecia, hyperkeratosis and intense pruritis. The 
dogs were of  various breeds, mainly mongrels were otherwise 
healthy at veterinary assessment on Day -7. Animals selected for 
the studies had not received any avermectin or milbemycin drugs 
nor had they been treated with an ectoparasiticide for at least 60 
days prior to the first administration of  treatment.
Dogs were housed individually under strict quarantine measures 
in pens that were approximately 3.7 m ×1.7 m with concrete 
flooring. The indoor sleeping area had under floor heating and 
the outdoor run area was covered to prevent exposure to rain. 
No contact between dogs was possible. The dogs were acclimated 
to the study conditions for 7 days prior to treatment, and were 
observed for general health at least once daily for the duration of  
the study. 
The animals were fed an appropriate maintenance ration of  a 
commercial dry dog feed for the duration of  the study. Water was 
available ad libitum.
Experimental design  
The dogs were divided into two groups, group MBO contains 
fifty dogs, were treated with milbemycin oxime (2 mg/kg bod-
yweight) orally, and applied weekly for continually three weeks, 
group vehicle consisting of  fifteen dogs, were treated with vehicle. 
Assessment
Counts of mites
Efficacy was based on the presence or absence of  mites or mite 
eggs, supported by the clinical signs associated with canine sar-
coptic mange. To assess the numbers of  S. scabiei mites, skin scrap-
ings (~4 cm2) were taken on Days-1, 14, 28, 42 and 56 from five 
different body areas those sites believed to be the most likely to 
yield mites, i.e. elbows, ear margins, and any papules or crusts 
from lesions with an active appearance. The overlying hair was 
clipped and the area was scraped until capillary bleeding occurred. 
Skin scraping sites were recorded and these sites and/or sites of  
new lesions were scraped at each subsequent examination. Each 
scraping was mounted in mineral oil and examined microscopi-
cally for live mites on the presence of  live or dead mites and mite 
eggs. The numbers of  S. scabiei mites (immatures and adults) and 
eggs counted in each scraping were recorded separately. If  dogs 
had no clinical signs of  sarcoptic mange (papules, crusts, erythe-
matous rash or alopecia) and were negative for mites on two pre-
vious scrapings, subsequent scrapings were not performed unless 
clinical signs (suitable sites) reappeared.
Clinical signs
Because of  difficulties in obtaining mites for accurate counts, false 
negatives could have been recorded, which would have resulted in 
an overestimation of  the success of  the treatments. To counter 
this possibility, clinical signs were also used to support the success 
of  treatment. The clinical signs and the extent of  sarcoptic mange 
lesions on each dog were assessed on the days when scrapings 
were made. The following parameters were assessed for each dog 
and recorded on silhouette diagrams (left- and right-hand side): 
Body areas covered by papules, encrustations, hyperkeratosis. 
Data analysis
Data analysis followed method described by Fourie et al (Fourie et 
al, 2007). That is: The number of  mites and eggs counted in the 
five skin scrapings were combined for each dog and served as the 
primary variable for treatment success. Percent efficacy, relative to 
pretreatment and based on geometric means (gm), was calculated 
from mite counts as follows:
% efficacy =
gm pretreatment - gm posttreatment
X 100
gm pretreatment
For treatment efficacy, only dogs assessed at the post-treatment 
evaluation were used in the pretreatment calculation. The treat-
ment success for each group was calculated from the proportion 
of  dogs with no live mites or eggs and expressed as a percentage. 
The occurrence of  clinical signs of  mange was calculated as the 
percentage of  dogs positive for each sign.
A semi-quantitative assessment of  hair regrowth was made rela-
tive to pretreatment for each post-treatment evaluation. The skin 
surface of  the dogs on which hair regrowth occurred, compared 
to the pretreatment observations, was graded as <50%, 50–90% 
and >90% hair regrowth occurred. 
An overall success rate was calculated and was defined as a dog 
that complied with all of  the following conditions: No live mites 
or eggs; A complete resolution of  the occurrence of  papules and 
crusts as assessed on Days 28 and 56; Markedly improved hair 
regrowth in area of  former alopecia.
Results 
Efficacy against sarcoptic mange
There only signs of  mild depression on the day of  treatment, and 
a transient and slight intestinal hyperperistalsis were observed in 
some dogs. All dogs recovered completely by day 2 after treat-
ment. 
All of  the dogs were positive for live mites or mite eggs prior to 
the first treatment (Day -1). Mite and egg counts as well as clinical 
evaluations showed that treatment with milbemycin oxime (2 mg/
kg) following three 7-day treatment interval regiments resulted in 
a rapid reduction in the signs of  sarcoptic mange (Tables 1, 2). In 
the group MBO, post-treatment number of  dogs with mites or 
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mite eggs in skin scrapings between 2 (Day 28) to 0 (D42) of  50 
dogs, mean mite counts varied between 0.2 (Day 28) and 0 (Day 
56), while in the group Vehicle post-treatment number of  dogs 
with mites or mite eggs in skin scrapings between 15 (Day 0) to 13 
(D56) of  15 dogs, mean mite counts varied between 7.0 (Day 0) 
and 6.5 (Day 56). The mean mite counts from skin scrapings per-
formed on days 14, 28, 42, and 56 demonstrated that, compared 
with the vehicle, milbemycin oxime treatment produced reduc-
tions of  83.3%, 96%, 100% and 100%, respectively. Five dogs and 
two dogs were positive for live mites or mite eggs on day 14 and 
day 28, resulting in 83.3% and 96% values (Table 1). Success rates 
(proportion of  mite free dogs) of  milbemycin oxime and vehicle 
treatment at the end of  the study were 100% and 13.3%.
Analysis of  variance showed that on day 0 (prior to treatment), 
the mean values were not significantly different between treat-
ment (P=0.545). analysis of  variance performed after treatment 
showed that on each assessment day, the mean values for the 
milbemycin oxime treatment was significantly lower than that for 
the vehicle treatment (P=0.000, P=0.000, P=0.000, and P=0.000 
for days 14, 28, 42, and 56; Table 1). Analysis of  variance, using 
Savage Scores, confirmed these statistical significances. Fisher’s 
Exact Test demonstrated that significantly fewer milbemycin oxi-
me-treated dogs had mites detected on skin scrapings than did the 
vehicle-treated dogs since day14 (P=0.000) (Table 1). 
Clinical signs
The presence of  papules, encrustations, hyperkeratosis and hair 
regeneration was evaluated for all dogs by using clinical assess-
ments made on days -1, 14, 28, 42 and 56 (Table 2). The preva-
lence of  each sign assessed on each day showed marked trends in 
overall reductions in severity for milbemycin oxime-treated dogs 
in comparison with those receiving the vehicle only, as illustrated 
by the assessments on days -1, 14, 28, and 56 (Table 2). On day -1, 
Table 1: Efficacy of  milbemycin oxime against naturally acquired infestations of  S. scabiei on dogs: summary of  mean mite 
and egg counts in skin scrapings ( x ±SD)
Number of  dogs with mites or mite eggs in skin scrapings
treatmenta D-1 D14 D28 D42 D56
Percentage of  dogs
MBO (50/50)100 (5/50)10 (2/50)4 (0/50)0 (0/50)0
Vehicle (15/15)100 (14/15)93.3 (15/15)100 (15/15)100 (15/15)100
P-valuesb 0.000 0.000 0.000 0.000
Number of  S. scabiei or mite eggs
MBO 6.88±0.30 0.05±0.22 0.20±0.63 0 0
Vehicle 7.00±1.02 7.00±1.01 5.55±0.60 6.05±1.00 6.45±0.60
Success rate(%)c
MBO - 90 96 100 100
Vehicle - 6.7 0 0 0
Percentage reductiond 83.3 96 100 100
P-valuese 0.545 0.000 0.000 0.000 0.000
a. Treatment were administered on days 0, 7 and 14. Skin scrapings were performed on days -1, 14, 28, 42, and 56; 
b. Statistical significance of  the difference in the presence or absence of  mites milbemycin oxime and vehicle treatments, using 
Fisher’s Exact Test( two-tailed);
c. Percent of  dogs that were mite free; 
d. Reduction calculated relative to the vehicle groups’ mean count;
e. Statistical significance of  the difference of  in mean mite or mite egg values between milbemycin oxime and vehicle.
Table 2: Efficacy of  milbemycin oxime against naturally acquired infestations of  S. scabiei on dogs: clinical signs of  mite 
infestation (%)
Clinical sign Percentage of  dogs with clinical signs of  S. scabiei infestation
treatment D-1 D14 D28 D42 D56
Papules MBO (5/50)10 (0/50)0.0 (0/50)0.0 (0/50)0.0 (0/50)0.0
Vehicle (2/15)13.3 (2/15)13.3 (3/15)20.0 (5/15)33.3 (6/15)40.0
Encrustations MBO (35/50)70.0 (17/50)34.0 (5/50)10.0 (0/50)0.0 (0/50)0.0
Vehicle (11/15)73.3 (12/15)80.0 (12/15) 80.0 (13/15)86.7 (15/15)100.0
Hyperkeratosis MBO (35/50)70.0 (18/50)36.0 (6/50)12.0 (2/50)4.0 (0/50)0.0
Vehicle (10/15)66.7 (11/15)73.3 (12/15) 80.0 (13/15)86.7 (15/15)100.0
Hair regeneration rate (%)a
<50 MBO (42/50)84.0 (5/50)10.0 (4/50)8.0 (0/50)0.0
Vehicle (11/15)73.3 (12/15)80.0 (13/15)86.7 (15/15)100.0
50~90 MBO (6/50)12.0 (30/50)60.0 (21/50)42.0 (0/50)0.0
Vehicle (4/15)26.7 (3/15)25 (2/15)13.3 (0/15)0.0
>90 MBO (2/50)4.0 (15/50)30.0 (25/50)50.0 (50/50)100.0
Vehicle (0/15)0.0 (0/15)0.0 (0/15)0.0 (0/15)0.0
a. Measure of  hair regrowth relative to Day-1 (reduction in the relative area affected by alopecia)
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papules were observed in at least 10% of  animals; encrustations 
and hyperkeratosis were observed in at least 66% of  both vehicle- 
and milbemycin oxime-treated dogs. As the studies progressed, 
clinical signs of  sarcoptic mange and alopecia were markedly re-
duced following milbemycin oxime treatment. At the end of  the 
study, papules, encrustations and hyperkeratosis has almost disap-
peared on Day 56, hair regrowth of  all the dogs achieved 90%. 
However, there was no improvement in the vehicle-treated dogs 
on day 56, clinical signs were still evident in those dogs. 
Discussion and Conclusion
The study was designed to demonstrate the efficacy of  milbe-
mycin oxime against infestations of  S. scabiei on dogs under field 
conditions, on the basis of  skin scriapings, no S. scabiei mites or 
eggs were recovered from milbemycin oxime–treated dogs after 
three doses, at 7-day interval, was highly effective in the treatment 
of  naturally acquired infestations of  S. scabiei on dogs. There was 
a 100% reduction in mean mite counts from deep skin scripings 
by 42 days after the first application. The treatments were well 
tolerated and safe. The quantitative mite count data were sup-
ported by the assessment of  clinical signs associated with canine 
sarcoptic mange, and milbemycin oxime was shown to markedly 
reduce the prevalence of  these signs compared with their preva-
lence in vehicle-treated dogs. The results of  this and other studies 
(Paradis, 1998; Mueller et al, 1999) show that the agents used as 
positive controls are efficacious in the treatment of  S. scabiei in-
festation in dogs when used according to their label recommenda-
tions, although repeated treatment may be necessary for control 
of  the infestation. Milbemycin oxime also has been demonstrated 
to be highly effective against naturally acquired infestations of  S. 
scabiei in dogs in other clinical studies following oral application 
(De Jaham and Henry, 1995; Miller et al, 1996).
Signs of  toxicosis of  avermectins are neurological and can include 
ataxia, abnormal behaviour, tremors, mydriasis, lethargy, weak-
ness, recumbency, apparent blindness, hypersalivation/ptyalism, 
coma, and death (Lovell, 1990). Milbemycin oxime in the treat-
ment for demodicosis can lead to lethargy and vomiting (Gar-
field and Reedy, 1992; Mueller and Bettenay, 1995; Paradis, 1999). 
During the study, there only signs of  mild depression on the day 
of  treatment, and a transient and slight intestinal hyperperistalsis 
were observed in some dogs. All dogs recovered completely by 
day 2 after treatment. 
Milbemycin oxime has been shown to have a broad range of  
efficacy against endo- and ecto-parasites of  dogs. The results of  
the study presented here indicate that weekly administration of  
milbemycin oxime is highly effective against natural infestations 
of  S. scabiei in dogs.
This study showed that treatment with milbemycin oxime at the 
proposed minimum commercial dose rate applied at 7-day in-
tervals rapidly reduced Sarcoptes mite infestations on dogs and 
resulted in a marked clinical improvement in the symptoms of  
mange. Milbemycin oxime pellet can potentially be used as a safe 
therapeutic agent for sarcoptic mange control in dogs.
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